Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 12,557

Document Document Title
WO/2017/160672A1
Modified Tryptamine, Tryptamine-2'-deoxy-uridine (TrpdU) and TrpdU-phosphoramidites for oligonucleotide synthesis are provided, as well as improved methods of their synthesis and oligonucleotides comprising at least one modified TrpdU nu...  
WO/2017/158624A1
The present disclosure provides novel crystalline sofosbuvir form- M3 and a process for the preparation of sofosbuvir form-M3. The crystalline sofosbuvir form-M3 disclosed herein may be useful in the formulation of pharmaceutical dosage ...  
WO/2017/161349A1
Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.  
WO/2017/157356A1
Compounds of general formulae6 and 13 where X is -NH-C(NH2)=N+H2 or -N+H3, Y is a linear oligomer consisting of arginine units terminated with an aminodimethylenamide unit (-Arg)n-NH-(CH2)2-NH2, where n = 6-10, or arginine-aminocaproic u...  
WO/2017/160741A1
The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.  
WO/2017/160793A1
Provided herein a re composition and process for using an electrochemica l device for the reduction of the oxidized state of phosphorylated or non-phosphorylated nicotinamide adenine dinucleotide to the reduced state in which unwanted pr...  
WO/2017/153936A1
This invention provides messenger RNA (mRNA) molecules comprising comprising an open reading frame that encodes a protein of interest, wherein said modified RNA comprises a modified nucleoside selected from the group consisting of: (I), ...  
WO/2017/155923A1
This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or t...  
WO/2017/153186A1
The present invention relates novel substituted nucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invent...  
WO/2017/154938A1
[Problem] The purpose of the present invention is to provide a method for uniformly and efficiently producing a sugar having a sulfate group and/or phosphate group in the molecule or a compound containing the sugar. [Solution] The presen...  
WO/2017/156380A1
This disclosure relates to certain N4-hydroxycytidine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of a Zika virus infection.  
WO/2017/143453A1
This disclosure provides methods and strategies for inhibiting the growth of TP53 wild-type cancer cells, comprising contacting the cell with 2',2'-difluoro-5-aza-2'- deoxycytidine or a 2',2'-difluoro-5-aza-2'-deoxycytidine prodrug. Also...  
WO/2017/145151A1
Disclosed herein is a process for preparing nicotinamide riboside (NR) from an NR precursor and a phosphate-binding agent in a solvent. The reaction-derived mixture comprising NR may be further used without further processing in a variet...  
WO/2017/144423A1
The present invention relates to a process for the synthesis of Sofosbuvir of formula (I) comprising the selective mono-deacetylation reaction of a compound of formula (V) to obtain a compound of formula (IV).  
WO/2017/143113A1
The present invention is directed to methods for the use of 5 '-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus- related diseases or conditions, eye disorders, cancer, or di...  
WO/2017/142984A1
The application provides methods for treatment or prophylaxis of Zika Virus mediated diseases with compounds of Formula I, wherein the variables R1, R2, R3, R4, R5, and Base are defined as described hereinabove.  
WO/2017/142913A1
A method for making a polynucleotide is provided that includes (a) delivering one or more reaction reagents including an error prone or template independent DNA polymerase, cations and a selected nucleotide to a reaction site including a...  
WO/2017/142054A1
Provided is an artificial nucleoside or an artificial nucleotide which can constitute an artificial oligonucleotide having excellent nuclease resistance. An artificial nucleoside or an artificial nucleotide, which is a compound represent...  
WO/2017/137374A1
The present invention concerns methods and approaches for modifying guanosine tetraphosphate (ppGpp) homeostasis in photosynthetic eukaryotes, in particular plants or algae, in order to modulate senescence for the remobilisation of nitro...  
WO/2017/124315A1
A method for enzymatic preparation of fludarabine phosphate, comprising reaction of fludarabine with a high-energy phosphate compound under the action of deoxyribonucleic acid kinase. According to said method, acetate kinase and acetyl p...  
WO/2017/127357A1
A DNA aptamer is provided that binds to a cholecystokinin B receptor (CCBKR), allowing for delivery of therapeutic agents or imaging agents to cells having the CCBKR. Compositions and methods of use are provided where the aptamer binds t...  
WO/2016/205738A3
The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.  
WO/2017/118355A1
Provided in the present application are a nucleotide derivative of a deuterated HCV (Hepatitis C Virus) NS5b inhibitor, or a pharmaceutically acceptable salt, stereoisomer, tauromer inhibitor thereof, and a use thereof in the preparation...  
WO/2017/120508A1
Compounds that modulate the conversion of AMP to adenosine by 5'- nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions ...  
WO/2017/115301A1
The present disclosure provides methods for the treatment of breast cancer, including triple negative breast cancer. Said methods comprise the administration of (a) a cationic liposomal formulation comprising a taxane, (b) a non-liposoma...  
WO/2017/109485A1
This invention relates to a crystalline form of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-(S)-phosphate.  
WO/2017/110317A1
A nicotinamide mononucleotide derivative represented by general formula (1) or a salt thereof. (In the formula, R1 and R2 each independently represent a hydrogen atom or an acyl group having 3-30 carbon atoms. A hydrocarbon group bonded ...  
WO/2017/104836A1
The present invention provides an oligonucleotide production method that includes: (1) a step in which a reaction liquid comprising a phosphite triester body (c) is obtained by condensing, in a nonpolar solvent, a nucleoside, nucleotide,...  
WO/2017/101785A1
Disclosed in the present invention are a prodrug comprising a nucleoside analog structure as shown in formula I, a tautomer thereof, a stereisomer thereof, a stereisomer mixture thereof or a pharmaceutically acceptable solvate thereof. A...  
WO/2017/101890A1
The present invention relates to a spiroketal derivative having formula (I), a preparation method therefor and an application. R1, R2, R3, R4, X and the A ring are defined in the description. The derivative is an intestine or kidney gluc...  
WO/2017/103109A1
The present invention relates to a polymorph of a compound of formula (I) This polymorph is particularly suitable in treating IPF by pulmonary administration.  
WO/2017/097973A1
The present invention relates to modified nucleosides which are linked to cargo molecules and which can be incorporated by DNA or RNA polymerases in strand synthesis. The present invention also relates to use of such modified nucleosides...  
WO/2017/098252A1
The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-p...  
WO/2017/093973A1
The present invention provides pure sofosbuvir and a process for the preparation of pure sofosbuvir and its intermediates.  
WO/2017/094011A1
The present invention relates to pharmaceutically acceptable salts of conjugates comprising a chemotherapeutic drug and an amino acid or a derivative thereof, which are readily taken up by a target cell and reduce side effects induced by...  
WO/2017/093317A1
A method for the mobilization of a transposable element is provided. The method comprises the steps of a) providing an inhibitor of DNA methylation, and/or an inhibitor of transcription, and b) contacting the inhibitor(s) with a cell com...  
WO/2017/096246A1
The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.  
WO/2017/090275A1
[Problem] To provide a drug that substitutes for injections (5-azacytidine or 2'-deoxy-5-azacytidine) that are clinically used as bone marrow tumor therapeutic drugs, said drug having high stability with respect to metabolic enzyme cytid...  
WO/2017/090264A1
[Problem] To provide a drug that substitutes for injections (5-azacytidine or 2'-deoxy-5-azacytidine) that are clinically used as bone marrow tumor therapeutic drugs, said drug having high stability with respect to metabolic enzyme cytid...  
WO/2017/087517A1
The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel prodrugs of the invention.  
WO/2017/087887A1
This disclosure is related to a method for determining the identity of a nucleotide residue of a single-stranded DNA or RNA, or sequencing DNA or RNA, in a solution using an ion-sensing field effect transistor and reversible nucleotide t...  
WO/2017/086397A1
Provided is a novel method for producing an oligonucleotide using a nucleoside or oligonucleotide that is easy to isolate and has high storage stability. A method for producing an oligonucleotide including a step for carrying out H-phosp...  
WO/2017/080973A1
The present invention relates to a compound of the general formula (1). wherein A is selected from a group of formula 2. B is selected from a group of formula 3. The compound of formula (1) is suitable for use in a method for treating a ...  
WO/2017/079195A1
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the d...  
WO/2017/076266A1
The present invention relates to a method for preparing (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-((2-(methylthio)ethyl)a mino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahyd rofuran-3,4-diol. Specifically, the present invention relat...  
WO/2017/077552A1
A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein.  
WO/2017/079745A1
Provided herein are methods of administering gapmer oligomeric compounds with GalNAc conjugate groups to a human.  
WO/2017/070464A1
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure (I) They are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.  
WO/2017/066791A1
The present disclosure relates to cap analogs of formula (I), which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for prepar...  
WO/2017/066571A1
Provided are methods and compositions for treating cancers in patients carrying an IDHl mutation using a combination of an inhibitor of a mutant IDHl enzyme and a DNA demethylating agent.  

Matches 401 - 450 out of 12,557